Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter

Alzheimer's treatment

  • Featured Story

    This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough

    new Alzheimer’s drug

    By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - September 25, 2014

    Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.

    But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.

    In other words, there is a way to both fight Alzheimer’s and supercharge your portfolio – today…

Article Index

  • This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough
  • Is This Drug the Key to an Alzheimer's Cure?
  • This Alzheimer's "Pacemaker" Could Be the Bridge to a Cure

This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough

By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - September 25, 2014

new Alzheimer’s drug

Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.

But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.

In other words, there is a way to both fight Alzheimer’s and supercharge your portfolio – today…

Is This Drug the Key to an Alzheimer's Cure?

By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - January 28, 2013

Among the top 10 causes of death by disease, Alzheimer's is the only one that cannot be cured, treated, or slowed down. But that may be about to change - and a vaccine could soon be at hand.

This Alzheimer's "Pacemaker" Could Be the Bridge to a Cure

By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - January 2, 2013

There's good news for Alzheimer's patients after all...

This news comes at an opportune time. Just last summer, the whole effort suffered a major setback.

That's when three Big Pharma firms said they were halting development of Alzheimer's compounds because the medicines simply didn't work. No doubt, that was a blow for both patients and investors in Eli Lilly & Co. (NYSE:LLY), Pfizer Inc. (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ).

But this month we learned that a research team at Johns Hopkins has for the first time implanted a promising device into the brain of a U.S. Alzheimer's patient. It seems to combat the effects of Alzheimer's by providing deep-brain stimulation. It works very much like the pacemaker that's normally used in the heart.

Over the next year or so, a total of 40 patients will receive the implants under a federally funded trial.

This is a big move with very promising potential. You see, doctors have used a similar device to control Parkinson's disease for about the past 15 years, with some 80,000 patients receiving the implants. They report having fewer seizures and needing less medication.

I believe this very well could be the bridge technology we need until a true "cure" for Alzheimer's is found. Right now, the chances look good that this interim step will succeed.

"This is a very different approach, whereby we are trying to enhance the function of the brain mechanically," says Dr. Paul B. Rosenberg. "It's a whole new avenue for potential treatment for a disease becoming all the more common with the aging of the population."

As high-tech investors, we need to keep an eye on this research and be ready to pounce when a medical-device maker gets it to market.

I don't know just when that will happen. But when it does, you can bet that I'll drop you a line.

Meantime, I have four more fascinating developments to share with you today.

Take a look...

To continue reading, please click here...

QUICK LINKS
About Us How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Login to Private Briefing

© 2022 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles Street | Baltimore, MD 21201 | USA | Phone: 888.384.8339 I Disclaimer | Sitemap | Privacy Policy | Whitelist Us